Clinical Trial Detail

NCT ID NCT02748564
Title Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Rutgers, The State University of New Jersey
Indications

skin melanoma

mucosal melanoma

melanoma

Therapies

Aldesleukin + Pembrolizumab

Age Groups: child adult

No variant requirements are available.